Sathanandam Shyam, Justino Henri, Waller B Rush, Gowda Srinath T, Radtke Wolfgang, Qureshi Athar M
University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, Tennessee.
The Lillie Frank Abercrombie Section of Cardiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
J Interv Cardiol. 2017 Apr;30(2):177-184. doi: 10.1111/joic.12369. Epub 2017 Feb 16.
To describe the early multi-center, clinical experience with the Medtronic Micro Vascular Plug™ (MVP) in children with congenital heart disease (CHD) undergoing vascular embolization.
The MVP is a large diameter vascular occlusion device that can be delivered through a microcatheter for embolization of abnormal blood vessels.
A retrospective review of embolization procedures using the MVP in children with CHD was performed in 3-centers. Occlusion of patent ductus arteriosus using the MVP was not included.
Ten children underwent attempted occlusion using the MVP. The most common indication to use the MVP was failed attempted occlusion using other embolic devices. Five, single ventricle patients (median age 3-years, median weight 14.9 kg) underwent occlusion of veno-venous collaterals following bidirectional Glenn operation. Three patients (Median age 8 years) underwent occlusion of coronary artery fistulae (CAF). Two patients (age 7 months and 1 year) underwent occlusion of large aorto-pulmonary collaterals. A 7-day-old child with a large CAF required 2 MVPs and an Amplatzer Vascular Plug (AVP-II) for complete occlusion. Occlusion of all other blood vessels was achieved using a single MVP. One MVP embolized distally in an 8-years-old child with a large CAF. There were no other procedural complications or during follow-up (median 9 months).
The MVP is a new, large-diameter vascular embolization device that can be delivered through a microcatheter. It may play an important role in providing highly effective occlusion of abnormal vessels in children.
描述美敦力微血管封堵器™（MVP）在接受血管栓塞术的先天性心脏病（CHD）患儿中的早期多中心临床经验。
MVP是一种大口径血管闭塞装置，可通过微导管输送用于栓塞异常血管。
对3个中心使用MVP对CHD患儿进行栓塞手术的情况进行回顾性分析。使用MVP封堵动脉导管未闭的情况不包括在内。
10名患儿尝试使用MVP进行封堵。使用MVP最常见的指征是使用其他栓塞装置封堵失败。5名单心室患儿（中位年龄3岁，中位体重14.9千克）在双向格林手术后接受了腔静脉侧支封堵。3名患儿（中位年龄8岁）接受了冠状动脉瘘（CAF）封堵。2名患儿（年龄分别为7个月和1岁）接受了大的主-肺动脉侧支封堵。一名7天大的患有大型CAF的患儿需要2个MVP和1个Amplatzer血管封堵器（AVP-II）才能完全封堵。所有其他血管的封堵均使用单个MVP完成。1个MVP在一名患有大型CAF的8岁患儿中远端栓塞。在手术过程中及随访期间（中位随访9个月）均无其他并发症。
MVP是一种新型的大口径血管栓塞装置，可通过微导管输送。它可能在为儿童异常血管提供高效封堵方面发挥重要作用。
